Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone415-374-7782
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$147.70 million
Profitability
Miscellaneous
Employees788
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable
InVitae (NYSE:NVTA) Frequently Asked Questions
What is InVitae's stock symbol?
InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."
How were InVitae's earnings last quarter?
InVitae Corp (NYSE:NVTA) posted its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.17. The medical research company had revenue of $56.51 million for the quarter, compared to the consensus estimate of $55 million. InVitae had a negative return on equity of 58.90% and a negative net margin of 99.49%. View InVitae's Earnings History.
When is InVitae's next earnings date?
What price target have analysts set for NVTA?
5 analysts have issued 12-month price targets for InVitae's shares. Their forecasts range from $20.00 to $34.00. On average, they expect InVitae's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 56.8% from the stock's current price. View Analyst Price Targets for InVitae.
What is the consensus analysts' recommendation for InVitae?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.
What are Wall Street analysts saying about InVitae stock?
Here are some recent quotes from research analysts about InVitae stock:
- 1. According to Zacks Investment Research, "Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California. " (1/16/2020)
- 2. Chardan Capital analysts commented, "We liked the new strategic partnerships with biopharma companies, growth in billable tests, and improvement in average cost per sample during the quarter. We see NVTA as a leader among high-growth digital health companies and we see the stock as mispriced compared with its valuation peers. We see the potential for over 50% upside in the name in the next 12 months as Management executes and the stock trades more in line with its valuation comparable." (6/11/2019)
Has InVitae been receiving favorable news coverage?
News headlines about NVTA stock have been trending extremely negative on Thursday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. InVitae earned a news impact score of -5.0 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for InVitae.
Are investors shorting InVitae?
InVitae saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 19,440,000 shares, an increase of 10.8% from the December 15th total of 17,550,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is presently 10.6 days. Approximately 20.8% of the shares of the company are sold short. View InVitae's Current Options Chain.
Who are some of InVitae's key competitors?
Some companies that are related to InVitae include ELEKTA AB/ADR (EKTAY), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Centogene (CNTG), Fulgent Genetics (FLGT), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).
What other stocks do shareholders of InVitae own?
Who are InVitae's key executives?
InVitae's management team includes the folowing people:
- Dr. Randal W. Scott, Exec. Chairman (Age 61)
- Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
- Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
- Mr. Lee Bendekgey, Sec. & COO (Age 61)
- Ms. Laura D'Angelo, Head of Investor Relations
When did InVitae IPO?
(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.
Who are InVitae's major shareholders?
InVitae's stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.77%), Profit Investment Management LLC (0.19%), Alpine Global Management LLC (0.01%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Exchange Traded Concepts LLC (0.00%). Company insiders that own InVitae stock include Bros Advisors Lp Baker, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida. View Institutional Ownership Trends for InVitae.
Which institutional investors are buying InVitae stock?
NVTA stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Alpine Global Management LLC, Profit Investment Management LLC, Exchange Traded Concepts LLC and Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have bought InVitae stock in the last two years include Bros Advisors Lp Baker and Randal W Scott. View Insider Buying and Selling for InVitae.
How do I buy shares of InVitae?
Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is InVitae's stock price today?
One share of NVTA stock can currently be purchased for approximately $18.50.
How big of a company is InVitae?
InVitae has a market capitalization of $1.79 billion and generates $147.70 million in revenue each year. The medical research company earns $-129,350,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. InVitae employs 788 workers across the globe.View Additional Information About InVitae.
What is InVitae's official website?
How can I contact InVitae?
InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]
MarketBeat Community Rating for InVitae (NYSE NVTA)
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
